Merck & Company, Inc. (MRK) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - General
Sell if holding. Analyst target reached at $119.05 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Keytruda (49.0%).
Merck is a global healthcare company operating Pharmaceutical (human drugs and vaccines) and Animal Health segments, with $65B in total sales in 2025. Revenue is driven by Keytruda ($31.7B), Gardasil/Gardasil 9 ($5.2B), and a broad portfolio of prescription medicines, vaccines,... Read more
Sell if holding. Analyst target reached at $119.05 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Keytruda (49.0%). Chart setup: RSI 42 mid-range, Bollinger mid-band. Score 5.8/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: conservative.
Recent developments
updated 2026-06-13Recent Developments — Merck & Company, Inc.
Latest news
- NEWS Merck (MRK) Q1 Earnings Report Preview: What To Look For - StockStory — StockStory neutral
- NEWS Why Merck (MRK) Shares Are Trading Lower Today - Yahoo Finance — Yahoo Finance negative
- NEWS Why Merck (MRK) Shares Are Trading Lower Today - StockStory — StockStory negative
- NEWS Merck & Co Inc Stock (MRK) Moved Down by 4.19% on Apr 21: A Full Analysis - TradingKey — TradingKey negative
- NEWS MRK Stock Soars As Keytruda Delivers Again In Q1, Winrevair Accelerates — CEO Signals Robust Phase 3 Readout Period Ahea — Stocktwits positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductKeytruda49%10-K Item 1A: 'in 2025, sales of Keytruda represented 49% of the Company's total sales'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $119.05 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Keytruda (49.0%). Chart setup: RSI 42 mid-range, Bollinger mid-band. Prior stop was $112.59. Score 5.8/10, moderate confidence.
Take-profit target: $120.99 (+1.6% upside). Prior stop was $112.59. Stop-loss: $112.59.
Concentration risk — Product: Keytruda (49.0%); Analyst target reached - limited upside remaining; Near 52-week high (4.9% away).
Merck & Company, Inc. trades at a P/E of 33.5 (forward 12.4). TrendMatrix value score: 5.2/10. Verdict: Sell.
36 analysts cover MRK with a consensus score of 3.9/5. Average price target: $130.
What does Merck & Company, Inc. do?Merck is a global healthcare company operating Pharmaceutical (human drugs and vaccines) and Animal Health segments,...
Merck is a global healthcare company operating Pharmaceutical (human drugs and vaccines) and Animal Health segments, with $65B in total sales in 2025. Revenue is driven by Keytruda ($31.7B), Gardasil/Gardasil 9 ($5.2B), and a broad portfolio of prescription medicines, vaccines, and animal health products sold to wholesalers, hospitals, and government entities worldwide.